Circulating Total Bilirubin and Future Risk of Hypertension in the General Population: The Prevention of Renal and Vascular End‐Stage Disease (PREVEND) Prospective Study and a Mendelian Randomization Approach
Open Access
- 1 November 2017
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 6 (11)
Abstract
Background: Circulating total bilirubin is known to be inversely and independently associated with future risk of cardiovascular disease. However, the relationship of circulating total bilirubin with incident hypertension is uncertain. We aimed to assess the association of total bilirubin with future hypertension risk and supplemented this with a Mendelian randomization approach to investigate any causal relevance to the association. Methods and Results: Plasma total bilirubin levels were measured at baseline in the PREVEND (Prevention of Renal and Vascular End‐Stage Disease) prospective study of 3989 men and women without hypertension. Hazard ratios (95% confidence intervals) of total bilirubin with incident hypertension were assessed. New‐onset hypertension was recorded in 1206 participants during a median follow‐up of 10.7 years. Baseline total bilirubin was approximately log‐linearly associated with hypertension risk. Age‐ and sex‐adjusted hazard ratio for hypertension per 1‐SD increase in log e total bilirubin was 0.86 (0.81–0.92; P P =0.040) after further adjustment for established risk factors and other potential confounders. The association was marginally significant on further adjustment for high‐sensitivity C‐reactive protein (0.94; 0.88–1.00; P =0.067). A genetic variant at the UGT 1A1*28 locus consistently shown to be strongly associated with circulating bilirubin levels—rs6742078—was not significantly associated with blood pressure or hypertension ( P >0.05 for all), arguing against a strong causal association of circulating bilirubin with blood pressure. Conclusions: The weak and inverse association of circulating total bilirubin with future hypertension risk may be driven by biases such as unmeasured confounding and/or reverse causation. Further evaluation is warranted.Keywords
This publication has 71 references indexed in Scilit:
- Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosisNature Medicine, 2013
- Estimating Glomerular Filtration Rate from Serum Creatinine and Cystatin CNew England Journal of Medicine, 2012
- Effect of Different Doses of Aerobic Exercise Training on Total Bilirubin LevelsMedicine & Science in Sports & Exercise, 2012
- Association between bilirubin and cardiovascular disease risk factors: using Mendelian randomization to assess causal inferenceBMC Cardiovascular Disorders, 2012
- Genetic variants in novel pathways influence blood pressure and cardiovascular disease riskNature, 2011
- Inflammation, Immunity, and HypertensionHypertension, 2011
- Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosisAtherosclerosis, 2010
- Inhibition of bilirubin metabolism induces moderate hyperbilirubinemia and attenuates ANG II-dependent hypertension in miceAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2009
- Serum Total Bilirubin Level, Prevalent Stroke, and Stroke Outcomes: NHANES 1999–2004The American Journal of Medicine, 2008
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studiesJournal of Clinical Epidemiology, 2008